Creating a new type of cell therapy to improve immune response control
Development of a cellular therapy product with single specificity and improved persistence to prevent immunity to biotherapeutics
This study is testing a new treatment that helps special immune cells called regulatory T cells work better in managing autoimmune diseases and hemophilia A, by giving them special tools to target a key protein, which could lead to longer-lasting and more effective relief from symptoms.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10894754 on NIH RePORTER |
What this research studies
This research focuses on developing a novel cellular therapy that enhances the ability of regulatory T cells (Tregs) to manage harmful immune responses in conditions like autoimmune diseases and hemophilia A. By engineering Tregs with specific receptors that target clotting factor VIII, the therapy aims to improve the effectiveness and longevity of these cells in the body. The approach utilizes advanced techniques such as CRISPR to create a more precise and durable immune response, potentially reducing the formation of anti-drug antibodies that can hinder treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with autoimmune diseases or hemophilia A who are experiencing issues with current therapies due to immune responses.
Not a fit: Patients with conditions unrelated to immune response or those who do not have autoimmune diseases or hemophilia A may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with autoimmune diseases and hemophilia A, improving their quality of life and treatment outcomes.
How similar studies have performed: Previous research has shown promise in using engineered Tregs for immune modulation, indicating that this approach could be a significant advancement in the field.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Biswas, Moanaro — Indiana University Indianapolis
- Study coordinator: Biswas, Moanaro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.